



19 March 2024

**Immupharma PLC**  
("Immupharma" or the "Company")

**Grant of Share Options**

Immupharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows.

The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting conditions which reflect the corporate objective of restoring and enhancing shareholder value as follows:

Tim McCarthy	8,000,000 share options (exercise price £0.02)
Tim Franklin	6,500,000 share options (exercise price £0.02)
Sebastien Goudreau	5,000,000 share options (exercise price £0.02)

In addition, 5,500,000 unapproved Share Options have been awarded to other employees/contractors with the same performance conditions.

Share Option Period: All Share Options are valid for 10 years from the date of issue.

Time and Performance Conditions:

All Share Options will vest at the latter of:

- When the Company has completed a new commercial deal of significant value; and
- 3 years from the date of issue

The Remuneration Committee will determine when these conditions have been met.

ENDS

For further information please contact:

<b>Immupharma PLC</b> ( <a href="http://www.immupharma.com">www.immupharma.com</a> )	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496

<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	

<b>Stanford Capital Partners (Joint Broker)</b>	+44 (0) 203 650 3650
Patrick Claridge, Bob Pountney	

<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	

**Notes to Editors**

**About Immupharma PLC**

Immupharma PLC (LSE: IMM) is a specialty biopharmaceutical company that discovers and develops

Immupharma PLC (LSE AIM: IMVM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Tim McCarthy
2	Reason for the notification	
a)	Position/status	Chairman and Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	ImmuPharma PLC
b)	LEI	213800VZKGHXC7VUS895
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	<b>Ordinary Shares of 1p each</b>
	Identification code	<b>ISIN: GB0033711010</b>
b)	Nature of the transaction	<b>Grant of share options over new Ordinary Shares</b>
c)	Price(s) and volume(s)	Exercise Price
		Volume
		<b>2 pence</b>
		<b>8,000,000</b>
d)	Aggregated information	N/A
	- Aggregated volume	
	- Price	
e)	Date of the transaction	18 March 2024
f)	Place of the transaction	n/a

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Tim Franklin
2	Reason for the notification	
a)	Position/status	Chief Operating Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	ImmuPharma PLC
b)	LEI	213800VZKGHXC7VUS895
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	<b>Ordinary Shares of 1p each</b>

	instrument, type of instrument		
	Identification code	<b>ISIN: GB0033711010</b>	
b)	Nature of the transaction	<b>Grant of share options over new Ordinary Shares</b>	
c)	Price(s) and volume(s)	Exercise Price	Volume
		<b>2 pence</b>	<b>6,500,000</b>
d)	Aggregated information	N/A	
	- Aggregated volume		
	- Price		
e)	Date of the transaction	<b>18 March 2024</b>	
f)	Place of the transaction	<b>n/a</b>	

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	<b>Sebastien Goudreau</b>	
2	Reason for the notification		
a)	Position/status	<b>Director</b>	
b)	Initial notification /Amendment	<b>Initial notification</b>	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	<b>ImmuPharma PLC</b>	
b)	LEI	<b>213800VZKGHC7VUS895</b>	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	<b>Ordinary Shares of 1p each</b>	
	Identification code	<b>ISIN: GB0033711010</b>	
b)	Nature of the transaction	<b>Grant of share options over new Ordinary Shares</b>	
c)	Price(s) and volume(s)	Exercise Price	Volume
		<b>2 pence</b>	<b>5,000,000</b>
d)	Aggregated information	N/A	
	- Aggregated volume		
	- Price		
e)	Date of the transaction	<b>18 March 2024</b>	
f)	Place of the transaction	<b>n/a</b>	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBCGDXSBBDSI